Knowledge Distillery

The CoronaVirus Disease 19 (COVID-19) pandemic is a threat of particular concern for people affected by chronic immune-mediated diseases, such as…

Multiple risk factors for mortality have been identified in patients with COVID-19.

Neurological manifestations are common in patients with COVID-19, but little is known about pathophysiological mechanisms. In this single-centre…

Narcolepsy type 1 (NT1) is a chronic rare hypersomnia of central origin requiring a combination of behavioural and pharmacological treatments. During…

The prolonged mechanical ventilation that is often required by patients with severe COVID-19 is expected to result in significant intensive care…

BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute…

LY-CoV555, a neutralising monoclonal antibody, has been associated with a decrease in viral load and frequency of hospitalisations or emergency…

Recent data suggest that complications and death from COVID-19 may be related to high viral loads.

The efficacy of interleukin-6 receptor blockade in hospitalised patients with COVID-19 who are not receiving mechanical ventilation is unclear.

Severe COVID-19 is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus…

NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length…

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been postulated to affect susceptibility to COVID-19.…